Home

Opposition Klasse Ei nmd pharme Schäkel Schulter Kristall

NMD Pharma raises $47M in series A investment round from INKEF and existing  investors, to advance treatments of neuromuscular disorders | Nordic 9
NMD Pharma raises $47M in series A investment round from INKEF and existing investors, to advance treatments of neuromuscular disorders | Nordic 9

NMD Pharma on Vimeo
NMD Pharma on Vimeo

NMD Pharma is Strengthening Muscles in Neuromuscular Disorders
NMD Pharma is Strengthening Muscles in Neuromuscular Disorders

NMD Pharma picked as Biotech of the Week by Labiotech.eu — NMD Pharma
NMD Pharma picked as Biotech of the Week by Labiotech.eu — NMD Pharma

NMD Pharma, finalist i Life Sciences kategorien - EY Danmark
NMD Pharma, finalist i Life Sciences kategorien - EY Danmark

NMD Pharma A/S | LinkedIn
NMD Pharma A/S | LinkedIn

Denmark in New York on Twitter:
Denmark in New York on Twitter: "#DKBIO17 is "a great opportunity for us to broaden our scope and look for investors.” - Thomas H. Pedersen, CEO, NMD Pharma… https://t.co/AUeO5JqgX6"

NMD Pharma - Inkef capital
NMD Pharma - Inkef capital

NMD Pharma Initiates a Combined Phase I/IIa Clinical Trial of NMD670 for  the Treatment of Symptoms of Myasthenia Gravis
NMD Pharma Initiates a Combined Phase I/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis

NMD Pharma company information, funding & investors | Dealroom.co
NMD Pharma company information, funding & investors | Dealroom.co

NMD Pharma — NMD Pharma
NMD Pharma — NMD Pharma

Klaus Wilhardt - Corporate identity, Design, Logo/navnetræk og designguides
Klaus Wilhardt - Corporate identity, Design, Logo/navnetræk og designguides

NMD Pharma
NMD Pharma

NMD Pharma A/S | LinkedIn
NMD Pharma A/S | LinkedIn

NMD Pharma Initiates a Combined Phase I/IIa Clinical Trial of NMD670 for  the Treatment of Symptoms of Myasthenia Gravis | MENAFN.COM
NMD Pharma Initiates a Combined Phase I/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis | MENAFN.COM

Nete Huus's email & phone | NMD Pharma ApS's Senior Scientist email
Nete Huus's email & phone | NMD Pharma ApS's Senior Scientist email

NMD Pharma Receives Approval to Start a combined Phase I/IIa Clinical Trial  of NMD670 for the Treatment of Symptoms of Myasthenia Gravis
NMD Pharma Receives Approval to Start a combined Phase I/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis

NMD Pharma - PIR International
NMD Pharma - PIR International

NMD Pharma Information | NMD Pharma Profile
NMD Pharma Information | NMD Pharma Profile

Company Presentation
Company Presentation

Erhverv Aarhus - 照片| Facebook
Erhverv Aarhus - 照片| Facebook

NMD Pharma - Inkef capital
NMD Pharma - Inkef capital

NMD Pharma | The Org
NMD Pharma | The Org

NMD Pharma company information, funding & investors | Dealroom.co
NMD Pharma company information, funding & investors | Dealroom.co

Prominent Canadian researcher in Denmark: Why I left a top job in California
Prominent Canadian researcher in Denmark: Why I left a top job in California

NMD Pharma is Strengthening Muscles in Neuromuscular Disorders
NMD Pharma is Strengthening Muscles in Neuromuscular Disorders